pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 12·1 min read
save

Bristol Myers joins Hengrui party in 13-asset deal worth up to $15.2B

It's becoming Hengrui Pharma's world, and some Western drugmakers are just living in it. China's largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bristol Myers Squibb as ...

May 12, 2026·read at Endpoints ↗

May 12, 2026 05:06 AM EDT DealsChinaPharma Bris­tol My­ers joins Hen­grui par­ty in 13-as­set deal worth up to $15.2B Kyle LaHucik Biotech Correspondent It’s be­com­ing Hen­grui Phar­ma’s world, and some West­ern drug­mak­ers are just liv­ing in it. Chi­na’s largest phar­ma com­pa­ny, which boasts one of the biggest pipelines … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
83 words · retrieved May 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
BRISTOL2BRISTOL MYERS SQUIBBBRISTOL MYERS SQUIBB COHENGRUI PHARMA

related stories

  • Aug 6Cardiac drug developer Braveheart banks more than $382M in IPOBioPharma Dive
  • Jul 30BMS CEO Boerner doesn’t ‘feel any compulsion to chase deals’ despite lack of M&A this yearFierce Biotech
  • Jul 15Braveheart, Attovia join next wave of biotech IPOsBioPharma Dive
  • Jun 3House bill aims to crack down on China biotech dealsBioPharma Dive
  • May 12STAT+: Hims’ sales miss as telehealth competition growsSTAT